Characteristic | Subcategory | Low risk | Intermediate risk | High risk | Weighted Kappa | ||||
---|---|---|---|---|---|---|---|---|---|
(n =231 ) | (n =215 ) | (n =28) | |||||||
Number | % | Number | % | Number | % | Correlation coefficient | P-value& | ||
Age at initial pathologic diagnosis | age < 50 | 36 | 19% | 53 | 20% | 4 | 17% | 0.02 | 0.55 |
50 <= age <=70 | 110 | 57% | 143 | 55% | 8 | 35% | Â | Â | |
age > 70 | 42 | 22% | 58 | 22% | 9 | 39% | Â | Â | |
*others/no information | 4 | 2% | 5 | 2% | 2 | 9% | Â | Â | |
Stage | Stage I-II | 22 | 11% | 13 | 5% | 0 | 0% | -0.06 | 0.026 |
Stage III | 145 | 76% | 203 | 78% | 18 | 78% | Â | Â | |
Stage IV | 25 | 13% | 42 | 16% | 5 | 22% | Â | Â | |
*others/no information | 0 | 0% | 1 | 0% | 0 | 0% | Â | Â | |
Grade | Grade 1 | 30 | 16% | 28 | 11% | 3 | 13% | -0.03 | 0.17 |
Grade 2 | 157 | 82% | 228 | 88% | 18 | 78% | Â | Â | |
Grade 3 | 1 | 1% | 0 | 0% | 0 | 0% | Â | Â | |
*others/no information | 4 | 2% | 3 | 1% | 2 | 9% | Â | Â | |
Tumor residual disease | No_Macroscopic_disease | 52 | 27% | 43 | 17% | 0 | 0% | 0.15 | 5.58E-4 |
1-20 mm | 83 | 43% | 144 | 56% | 11 | 48% | Â | Â | |
>20_mm | 27 | 14% | 42 | 16% | 7 | 30% | Â | Â | |
*others/no information | 30 | 16% | 30 | 12% | 5 | 22% | Â | Â | |
Primary therapy outcome success | Complete response | 130 | 68% | 133 | 51% | 5 | 22% | 0.15 | 1.12E-3 |
Partial response/stable disease | 23 | 12% | 49 | 19% | 7 | 30% | Â | Â | |
Progressive disease | 11 | 6% | 23 | 9% | 1 | 4% | Â | Â | |
*others/no information | 28 | 15% | 54 | 21% | 10 | 43% | Â | Â | |
^TCGA samples by molecular subtypes | Proliferative | 61 | 32% | 60 | 23% | 3 | 13% | 0.23 | 4.23E-8 |
Immunoreactive/Differentiated | 102 | 53% | 118 | 46% | 6 | 26% | Â | Â | |
Mesenchymal | 16 | 8% | 71 | 27% | 13 | 57% | Â | Â | |
*others/no information | 13 | 7% | 10 | 4% | 1 | 4% | Â | Â | |
^TCGA samples by miRNA clustering | C1 | 54 | 28% | 59 | 23% | 0 | 0% | -0.07 | 0.034 |
C2 | 12 | 6% | 89 | 34% | 20 | 87% | Â | Â | |
C3 | 113 | 59% | 101 | 39% | 2 | 9% | Â | Â | |
*others/no information | 13 | 7% | 10 | 4% | 1 | 4% | Â | Â | |
let-7b miRNA Classifier | Low Risk | 119 | 62% | 40 | 15% | 0 | 0% | 0.43 | <1E-16 |
Intermediate Risk | 72 | 38% | 196 | 76% | 9 | 39% | Â | Â | |
High Risk | 1 | 1% | 23 | 9% | 14 | 61% | Â | Â |